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Abstract
L-Threonine, technically pure, is a feed additive produced by fermentation using a genetically modiﬁed
(GM) strain of Escherichia coli (CGMCC 7.58). The Panel on Additives and Products or Substances used
in Animal Feed (FEEDAP Panel) of EFSA issued an opinion on the safety and efﬁcacy of the product,
which concluded that the recipient strain and its genetic modiﬁcation, including the presence or
absence of an antibiotic resistance gene in the product under assessment, are insufﬁciently
characterised. Consequently, the FEEDAP Panel could not make a conclusion on the safety of the
product L-threonine produced by fermentation with this recombinant strain of E. coli for target animals,
consumers, users and the environment. Furthermore, the level of endotoxins present in the product
and its dusting potential represent a risk for the user by inhalation. The European Commission asked
EFSA to deliver an opinion on the safety of L-threonine for all animal species based on additional data
submitted by the applicant on the characterisation of the additive and of the genetic modiﬁcation of
the production strain. No recombinant antibiotic resistance genes are present in the production strain
and therefore in the ﬁnal product. L-Threonine technically pure, manufactured by fermentation using
E. coli CGMCC 7.58, does not raise safety concerns for the target species, consumers, users and the
environment with regard to the genetic modiﬁcation of the production strain. A risk from exposure to
endotoxins for people handling the additive is expected. Concerns remain about possible dermal
sensitisation.
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on L-threonine,
technically pure, produced by fermentation using the genetically modiﬁed (GM) strain Escherichia coli
CGMCC 7.58 for all animal species.
In 2015, FEEDAP Panel of the European Food Safety Authority (EFSA) adopted an opinion on the
safety and efﬁcacy of L-threonine produced by fermentation using E. coli CGMCC 7.58. In that opinion,
the FEEDAP Panel concluded that the recipient strain and its genetic modiﬁcation, including the
presence or absence of an antibiotic resistance gene in the product under assessment, are
insufﬁciently characterised. Consequently, the FEEDAP Panel could not make a conclusion on the safety
of the product L-threonine produced by fermentation with this recombinant strain of E. coli for target
animals, consumers, users and the environment. Furthermore, the level of endotoxins present in the
product and its dusting potential were found to have an inhalation risk for the user.
The applicant provided additional information in relation to the characterisation of the additive, the
genetic modiﬁcation process of the production strain and the production process. The FEEDAP
Panel has performed the assessment of those new data following an approach in line with the
principles laid down in Regulation (EC) No 429/2008 and the relevant guidance documents.
This product was characterised in a previous scientiﬁc opinion (EFSA FEEDAP Panel, 2015).
The production strain is a derivative of E. coli K-12, which is considered safe. No recombinant
antibiotic resistance genes are present in the production strain and therefore in the ﬁnal product.
L-Threonine technically pure, manufactured by fermentation using E. coli CGMCC 7.58, does not raise
safety concerns for the target species, consumers, users and the environment with regard to the
genetic modiﬁcation of the production strain.
Due to improvements at several steps of the manufacturing process, the level of endotoxins
present in the product and its dusting potential have been reduced. Nevertheless, endotoxins
represent still a health risk for the user upon inhalation. In the absence of any data on sensitisation,
the product should be considered as a potential dermal sensitiser.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1831/2003 establishes rules governing the Community authorisation of additives
for animal nutrition and, in particular, Article 9 deﬁnes the terms of the authorisation by the
Commission.
The applicant, Feedway Europe NV, is seeking a Community authorisation of L-threonine, technically
pure to be used as a nutritional additive for all animal species (Table 1).
On 10 March 2015, the Panel on Additives and Products or Substances used in Animal Feed
(FEEDAP Panel) of the European Food Safety Authority (EFSA), in its opinion concluded that the
recipient strain and its genetic modiﬁcation, including the presence or absence of an antibiotic
resistance gene in the product under assessment, are insufﬁciently characterised. Consequently, the
FEEDAP Panel could not make a conclusion on the safety of the product L-threonine produced by
fermentation with this recombinant strain of E. coli for target animals, consumers, users and the
environment. Regardless of the assessment of the genetic modiﬁcation, the FEEDAP Panel had
concerns with respect to the microbial contamination of the product and the safety of the
simultaneous oral administration of L-threonine via water for drinking and feed. Finally, the level of
endotoxins present in the product and its dusting potential were found to have an inhalation risk for
the user.
The Commission gave the possibility to the applicant to submit complementary information in order
to complete the assessment on the safety and to allow a revision of Authority’s opinion.
The Commission has now received new data on the safety of L-threonine, technically pure produced
by Escherichia coli.
In view of the above, the Commission asks the Authority to deliver a new opinion on the safety of
L-threonine, technically pure as nutritional additive for all animal species based on the additional data
submitted by the applicant.
1.2. Additional information
L-Threonine (minimum content of L-threonine 98%, ‘as is’ basis) was ﬁrst authorised for use in
animal nutrition by Directive 88/485/EEC. It is currently included in the European Union Register of
Feed Additives pursuant to Regulation (EC) No 1831/2003 concerning additives in feedingstuffs.
The applicant has provided additional information on the physical properties of the additive, the
genetic modiﬁcation of the production strain and on the production process.
Although the additive was initially intended to be used in all animal species as a nutritional additive
(functional group amino acids, their salts and analogues) to feed and to water for drinking, during the
assessment, the applicant requested to withdraw the use of the additive in water for drinking.1
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier2 following a previous application on the same product.3
Table 1: Description of the substances
Category of additive Nutritional additive
Functional group of additive Amino acids, their salts and analogues
Description L-Threonine, technically pure
Target animal category All animal species
Applicant Feedway Europe NV
Type of request New opinion
1 Technical dossier/Correspondence and mandate/FAD-2015-0029 withdrawal partial app to EC and to EFSA.
2 FEED dossier reference: FAD-2015-0029.
3 FEED dossier reference: FAD-2010-0291.
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2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety of L-threonine produced by E. coli
CGMCC 7.58 is in line with the principles laid down in Regulation (EC) No 429/20084 and the relevant
guidance documents: Guidance on nutritional additives (EFSA FEEDAP Panel, 2012a), Guidance on
studies concerning the safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012b),
and Guidance on the risk assessment of genetically modiﬁed microorganisms and their products
intended for food and feed use (EFSA GMO Panel, 2011).
3. Assessment
The current application is for the authorisation of L-threonine produced by a genetically modiﬁed
(GM) strain of E. coli (CGMCC 7.58). It is intended to be used in all animal species as a nutritional
additive (functional group amino acids, their salts and analogues) to feed.
3.1. Characterisation
This product has been characterised in a previous opinion (EFSA FEEDAP Panel, 2015), with the
exception of the production strain, which was not adequately identiﬁed, and the genetic modiﬁcation,
for which the absence of antibiotic resistance genes in the production strain (and therefore in the
product), was insufﬁciently proven.
Additional data have been submitted on the genetic modiﬁcation process of the production strain,
the physicochemical properties of the additive and on its manufacturing process.
3.1.1. Impurities
The previously assessed product had an average endotoxin activity (two batches analysed) of 927
International units of endotoxin activity (IU)/mg.5 An improvement has been introduced in the
downstream process to reduce the amount of bacterial endotoxins in the ﬁnal product. The ﬁltration
by ceramic membrane has been modiﬁed (from a former pore size of 300 kDa to the current smaller
size of 20 kDa); reverse osmosis has also been applied to reduce the amount of endotoxins in the
process water.6 New data have been submitted on the bacterial endotoxin activity of the product,
measured in three batches. The values ranged from < 0.50 to 1.44 IU/mg (European Pharmacopoeia
2.6.14 method).7
In March 2015 assessment, it was noted that one batch had > 10,000 total aerobic count colony-
forming units (CFU)/g and it was recommended to review the production process to ensure that the
microbial contamination of the product is low. The applicant has now provided microbiological analyses
(three batches) of total aerobic counts showing that no colonies were found after aerobic incubation of
100 lL of a 5% solution on LB medium at 37°C for 48 h. The production strain, when used as positive
control, performed as expected.8 The previous opinion indicated that the numbers of yeasts
(< 100 CFU/g) and ﬁlamentous fungi (≤ 150 CFU/g) were low, and that Salmonella spp. were absent
in 25 g samples. No data on these were provided in the new application.
3.1.2. Physical properties
The applicant stated that the downstream process had been modiﬁed to increase the crystal size of
the ﬁnal product and consequently decrease its dustiness. The evaporation temperature has been
lowered (75–72°C), the evaporation rate reduced (2.5–2.0 m3/h), the evaporation time prolonged
(12–15 h) and the cooling time extended from 3 to 5 h.9
4 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
5 Technical dossier FAD-2010-0291/Supplementary information January 2013/Attachment 3.
6 Technical dossier/Supplementary information March 2016/Attachment 1.
7 Technical dossier/Technology improvement on production process, Supplementary information on endotoxin levels and
Attachments 1–3.
8 Technical dossier/Supplementary information March 2016/Attachment 10.
9 Technical dossier/Technology improvement on production process.
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New analytical data have been provided to characterise the particle size and dustiness of the new ﬁnal
product. The particle size distribution (three batches analysed by laser diffraction) indicated a fraction of
59–60% (v/v) particles < 100 lm, of 24–26% (v/v) of particles < 50 lm and 3% (v/v) of particles
< 10 lm diameter (mean diameter of the particles of the additive was about 85 lm).10 The former
product (ﬁve batches analysed, method not speciﬁed) showed a range of 69–75% of particles having a
diameter < 100 lm and a range of 12–15% of particles having a diameter < 50 lm; one additional batch
analysed by sieving had about 16% (w/w) of the particles with a diameter < 50 lm.11 The dusting
potential (three batches analysed by the Stauber–Heubach method) ranged from 0.74 to 1.25 g/m3.12
The dusting potential of the product assessed in 2015 (one batch analysed) was 2.4 g/m3.13
3.1.3. Characterisation of the production microorganism E. coli CGMCC 7.5814
In the former dossier submitted for the characterisation of the production strain (EFSA FEEDAP
Panel, 2015), no data were provided to conﬁrm the identity of the recipient strain. Moreover, no
conclusive evidence was provided regarding the absence of an antibiotic resistance gene (which was
transiently used in the genetic modiﬁcation) in the genome of the production strain or in the product.
Therefore, uncertainty remained regarding the identity and safety of the production strain and of the
product.
New data were provided in the dossier submitted for the present evaluation, which conﬁrmed the
identity of the production strain as E. coli K-12 derivative.15
Furthermore, the applicant provided an analysis indicating that the antibiotic resistance gene is not
present in the production strain.16
3.2. Safety
In its previous assessment (EFSA FEEDAP Panel, 2015), the FEEDAP Panel could not conclude on
the safety of the product L-threonine produced by fermentation with this recombinant strain of E. coli
for target animals, consumers, users and the environment. The reason was that the recipient strain
and its genetic modiﬁcation, including the presence or absence of an antibiotic resistance gene in the
production strain (and therefore in the product), were insufﬁciently characterised.
The production strain has been adequately identiﬁed as an E. coli K-12 derivative. E. coli K-12 is
considered safe. The applicant provided evidence that the production strain does not carry the
antibiotic resistance genes transiently used during the genetic modiﬁcation. Absence in the product of
recombinant DNA corresponding to the inserted sequences was previously shown (EFSA FEEDAP
Panel, 2015). Therefore, L-threonine, manufactured by fermentation with E. coli CGMCC 7.58, does not
raise any safety concern for the target species, the consumer, the user and the environment with
regard to the genetic modiﬁcation of the production strain.
3.2.1. Safety for the user
In the former opinion (EFSA FEEDAP Panel, 2015), it was concluded that there were no concerns
for users in respect of irritation to skin or eyes but that the product may have the potential to be a
dermal sensitiser and should be handled accordingly. The level of endotoxins present in the product
and its dusting potential indicated a risk for the user by inhalation.
No additional toxicity studies have been submitted on skin sensitisation potential of the product.
3.2.1.1. Effects on the respiratory system
Although a previous assessment was performed in 2015 (EFSA FEEDAP Panel, 2015), the
technological improvement in the manufacturing process makes necessary to re-assess the relevance
of the bacterial endotoxin activities found in the ﬁnal product for the user when exposed by inhalation.
10 Technical dossier/Supplementary information March 2016/Attachments 4 and 5.
11 Technical dossier FAD-2010-0291/Section II.1.5 and Annex II.1.1.
12 Technical dossier/Supplementary information March 2016/Attachment 4.
13 Technical dossier FAD-2010-0291/Supplementary information January 2013/Attachment 4.
14 This section has been amended following the applicable provisions on conﬁdentiality.
15 Technical dossier/Supplementary information March 2016/Attachment Conf 1 L-Threonine molecular identiﬁcation.
16 Technical dossier/Supplementary information March 2016/Attachment Conf 2 L-Threonine detection of antibiotic-resistant.
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The bacterial endotoxin activity (the three new batches) was up to 1.44 IU/mg.17 The dusting
potential ranges from 0.74 to 1.25 g/m3.18
The scenario used to estimate the exposure of persons handling the additive to endotoxins in the
dust, based on the EFSA Guidance on user safety (2012b) is described in Appendix A. The health-
based recommended threshold for the quantity of inhaled endotoxins per working day is 900 IU,
derived from provisional occupational exposure limits given by the Dutch Expert Committee on
Occupational Safety (DECOS) (Health Council of the Netherlands, 2010) and the Health and Safety
Executive (HSE, 2013). Based on the calculation of the potential endotoxin content in dust (Wallace
et al., 2016), the inhalation exposure could be up to 1,000 endotoxin IU per 8-h working day,
indicating a risk from the exposure to endotoxins for people handling the additive.
3.2.1.2. Conclusions on safety for the user
The product L-threonine produced by E. coli CGMCC 7.58 is not irritant but is a potential skin
sensitiser. It is a risk for the users by inhalation.
4. Conclusions
The production strain is an E. coli K-12 derivative. No recombinant antibiotic resistance genes are
present in the production strain and therefore in the ﬁnal product. L-Threonine manufactured by
fermentation with E. coli CGMCC 7.58 does not raise safety concerns for the target species,
consumers, users and the environment with regard to the genetic modiﬁcation of the production
strain.
The level of endotoxins present in the product and its dusting potential indicate a health risk for the
user upon inhalation. The product should be considered as a potential dermal sensitiser.
Documentation provided to EFSA
1) Dossier L-Threonine produced by Escherichia coli for all animal species. October 2015.
Submitted by Feedway Europe NV.
2) Dossier L-Threonine produced by Escherichia coli for all animal species. Supplementary
information. November 2015. Submitted by Feedway Europe NV.
3) Dossier L-Threonine produced by Escherichia coli for all animal species. Supplementary
information. March 2016. Submitted by Feedway Europe NV.
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Abbreviations
CGMCC China General Microbiological Culture Collection Center
CFU colony-forming unit
DECOS Dutch Expert Committee on occupational safety
FEEDAP EFSA Panel on Additives and Products or Substances Used in Animal Feed
GM genetically modiﬁed
GMO EFSA Panel on Genetically Modiﬁed Microorganisms
HSE British Health Safety Executive
IU International unit of endotoxin activity. One IU corresponds to one EU
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Appendix A – Safety for the user
The effects of the endotoxin inhalation and the exposure limits have been described in a previous
opinion (EFSA FEEDAP Panel, 2015).
Calculation of maximum acceptable levels of exposure from feed additives
The likely exposure time according to EFSA guidance (EFSA FEEDAP Panel, 2012b) for additives
added in premixtures assumes a maximum of 40 periods of exposure per day, each comprising 20 s,
equal to 800 s per day. With an uncertainty factor of 2, maximum inhalation exposure would occur for
2 9 800 = 1,600 s (0.444 h per day). Again, assuming a respiration volume of 1.25 m3/h, the
inhalation volume providing exposure to potentially endotoxin-containing dust would be
0.444 9 1.25 = 0.556 m3 per day. This volume should contain no more than 900 International unit of
endotoxin activity (IU) endotoxin, so the dust formed from the product should contain no more than
900/0.556 = 1,619 IU/m3.
Calculation of endotoxin content of dust
Two key measurements are required to evaluate the potential respiratory hazard associated with
endotoxin content of the product (the dusting potential of the product, expressed in g/m3; the
endotoxin activity of the dust, determined by the Limulus amoebocyte lysate assay (expressed in
IU/g)).19 If data for the dust are not available, the content of endotoxins of the product can be used
instead. If the content of endotoxins of the relevant additive is a IU/g and the dusting potential is b g/m3,
then the content of endotoxins of the dust in the air, c IU/m3, is obtained by the simple multiplication
a 9 b. This resulting value is further used for calculation of potential inhalatory exposure by users to
endotoxin from the additive under assessment (Table A.1) (EFSA FEEDAP Panel, 2012b).
Table A.1: Estimation of user exposure to endotoxins from the additive L-threonine produced by
Escherichia coli CGMCC 7.58, including consideration of using ﬁlter half mask (FF P2 or
FF P3)(a) as a preventative measure
Calculation Identiﬁer Description Amount Source
a Endotoxin content IU/g product 1,440 Technical dossier
b Dusting potential (g/m3) 1.25 Technical dossier
a 9 b c Endotoxin content in the air (IU/m3) 1,800
d No of premixture batches made/working
day
40 EFSA FEEDAP Panel
(2012b)
e Time of exposure (s)/production of one
batch
20 EFSA FEEDAP Panel
(2012b)
d 9 e f Total duration of daily exposure/worker (s) 800
g Uncertainty factor 2 EFSA FEEDAP Panel
(2012b)
f 9 g h Reﬁned total duration of daily exposure (s) 1,600
h/3 600 i Reﬁned total duration of daily exposure (h) 0.44
j Inhaled air (m3)/8-h working day 10 EFSA FEEDAP Panel,
2012b
j/8 9 i k Inhaled air during exposure (m3) 0.556
c 9 k l Endotoxin inhaled (IU) during
exposure/8-h working day
1,000
m Health-based recommended exposure limit
of endotoxin (IU/m3)/8-h working day
90 Health Council of the
Netherlands (2010)
m 9 j n Health-based recommended exposure
limit of total endotoxin exposure (IU)/
8-h working day
900
19 The Limulus amebocyte lysate is an aqueous extract of circulating amebocytes from the horseshoe crab (Limulus
polyphemus). This extract reacts with minute quantities of bacterial endotoxin (lipopolysaccharide from the walls of Gram-
negative bacteria) and this reaction is the basis of the assay used for the detection and quantiﬁcation of bacterial endotoxins.
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Calculation Identiﬁer Description Amount Source
l/10 Endotoxins inhaled (IU)/8-h working day
reduced by ﬁlter half mask FF P2 (reduction
factor 10)
100
l/20 Endotoxins inhaled (IU)/8-h working day
reduced by ﬁlter half mask FF P3 (reduction
factor 20)
50
(a): Filtering face piece or ﬁltering half mask according to European standard EN 149. They are graded from 1 to 3 depending on
their ﬁltering capacity.
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